chrisvoncsefalvay/vaers-outcomes huggingface dataset:
low energy (mild); itching (mild); Skin reaction (mild); rash all over the body (mild); headaches (mild); This spontaneous case was reported by a physician and describes the occurrence of ASTHENIA (low energy (mild)), PRURITUS (itching (mild)), SKIN REACTION (Skin reaction (mild)), RASH (rash all over the body (mild)) and HEADACHE (headaches (mild)) in a 46-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     Concomitant products included ATORVASTATIN for an unknown indication.    In October 2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. In October 2021, the patient experienced ASTHENIA (low energy (mild)), PRURITUS (itching (mild)), SKIN REACTION (Skin reaction (mild)), RASH (rash all over the body (mild)) and HEADACHE (headaches (mild)). The patient was treated with CYPROHEPTADINE for Itching, at an unspecified dose and frequency. At the time of the report, ASTHENIA (low energy (mild)), PRURITUS (itching (mild)), SKIN REACTION (Skin reaction (mild)), RASH (rash all over the body (mild)) and HEADACHE (headaches (mild)) outcome was unknown.        mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosing remained unchanged.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No medical history was provided by the reporter.   This case was linked to MOD-2021-414672 (Patient Link).
the day of the injection arm pain at injection site.  Later at 1:00am I had body ache, muscle and joint pain and fatigue. On following day  early in the evening I lost the ability total ability to speak.  I had a severe stutter. I was rushed to the hospital via ambulance.  I remained in the hospital and was released on Feb. 8
Rash/heat localized to site of injection, rash enlarged slightly over period of 3 days before fading; mild fever for 2 days (6/15-6/16); general malaise. Fever and apparent discomfort treated with infant TYLENOL and cool rag to head.
Received flu shot and was driving home when about 30 min later, I developed double vision. Was sent to ER when doctors thought it was my brain tumors growing. Had a CT and MRI of brain which shown tumors weren't growing. Sent home after EKG and labs were good. Double vision continued and right became crooked and turned inward and vision worsen. Given steroids and symptoms cleared about an hour later. Then returned on and off during weekend. Continue on steroids.
"Received flu and Covid booster Monday 11am.  Wednesday about noon experienced really weird vertigo.  My balance was way off and the spinning sensation upset my stomach and I vomited many times between 1 and 5 pm.  Recovered by 11 pm and was back to 90% Thursday am.  I have never experienced vertigo before"
All of a sudden, I felt a wet sensation on my scalp and it sounds like I am hearing through water...similar to swimmers ear.
She began complaining of lightheadedness,  body tingling, specifically the ears, flushed neck and face. Placed her in supine position on a mat table with legs elevated slightyl. Vitals were BP - 120/70, pulse 88, resp 20, Pulse ox - 99%. blood sugar -131, gave her juice, placed cold compresses on her forehead and neck, and administered Benedryl 50mg po.  Continued to monitor her and she recovered after 30 minutes. Not pregnant.
I had a tooth extracted on 8/19 had issues lost taste smell was given amoxicillin and 5 day supply of steroid pills. that was done by 8/25. i was traveling from 8/21 to 8/28. When i got home had a rapid test for covid came in negative. On Wednesday 9/1 / i had another tests and was told on 9/2 that it was positive. i had no smell or taste for 2 weeks my taste came back last night. No fever just congested and slight headache as of now.
fatigue; her arm ached; This is a spontaneous report received from non-contactable reporter(s) (Consumer or other non HCP) from a sales representative. The reporter is the patient.  A 47 year-old female patient received bnt162b2 (BNT162B2) (Batch/Lot number: unknown) as dose 2, single and (Batch/Lot number: unknown) as dose 1, single for covid-19 immunisation. Relevant medical history included: "Amlyodosis" (unspecified if ongoing), notes: Patient has amlyodosis and had stem cell transplant 6 years ago; "Stem cell" (unspecified if ongoing), notes: Patient has amlyodosis and had stem cell transplant 6 years ago. The patient's concomitant medications were not reported. The following information was reported: FATIGUE (non-serious), outcome "unknown", described as "fatigue"; PAIN IN EXTREMITY (non-serious), outcome "unknown", described as "her arm ached".  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
showed increased Hemoglobin and Hematocrit.; Hemoglobin and Hematocrit.; This case was reported by a consumer and described the occurrence of hemoglobin increased in a adult patient who received Herpes zoster (Shingrix) for prophylaxis.   On 1st November 2019, the patient received Shingrix. On 6th November 2019, 5 days after receiving Shingrix, the patient experienced hemoglobin increased and hematocrit increased. On an unknown date, the outcome of the hemoglobin increased and hematocrit increased were unknown.   It was unknown if the reporter considered the hemoglobin increased and hematocrit increased to be related to Shingrix.  Additional details were reported as follows: The age at vaccination was not reported. The age group was not reported but was selected as an adult as per vaccine indication.  The patient experienced hemoglobin increased and hematocrit increased after receiving Shingrix.
Admit to hospital after loss of consciousness. Thought to be fainting, family concerned re: seizure. Admit for brain MRI, EEG, echocardiogram. Results normal.
Vial initially stored in the refrigerator on 21-Apr-2022 and then administered on 02-Jun-2022; No adverse event; Dose administered after 30-day Use By Date; Dose 1 administered on 19-Apr-2022 and Dose 2 administered on 02-Jun-2022; This spontaneous case was reported by an other health care professional and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Dose administered after 30-day Use By Date), INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Dose 1 administered on 19-Apr-2022 and Dose 2 administered on 02-Jun-2022), PRODUCT STORAGE ERROR (Vial initially stored in the refrigerator on 21-Apr-2022 and then administered on 02-Jun-2022) and NO ADVERSE EVENT (No adverse event) in a 36-year-old female patient who received mRNA-1273 (Spikevax) (batch nos. 002M21A and 002M21A) for COVID-19 vaccination.     No Medical History information was reported.   On 19-Apr-2022, the patient received first dose of mRNA-1273 (Spikevax) (Intramuscular) 1 dosage form. On 02-Jun-2022, received second dose of mRNA-1273 (Spikevax) (Intramuscular) dosage was changed to 1 dosage form. On 02-Jun-2022, the patient experienced EXPIRED PRODUCT ADMINISTERED (Dose administered after 30-day Use By Date) and INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Dose 1 administered on 19-Apr-2022 and Dose 2 administered on 02-Jun-2022). On an unknown date, the patient experienced PRODUCT STORAGE ERROR (Vial initially stored in the refrigerator on 21-Apr-2022 and then administered on 02-Jun-2022) and NO ADVERSE EVENT (No adverse event). At the time of the report, EXPIRED PRODUCT ADMINISTERED (Dose administered after 30-day Use By Date), INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Dose 1 administered on 19-Apr-2022 and Dose 2 administered on 02-Jun-2022), PRODUCT STORAGE ERROR (Vial initially stored in the refrigerator on 21-Apr-2022 and then administered on 02-Jun-2022) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 (Spikevax) (Intramuscular), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessments were provided for EXPIRED PRODUCT ADMINISTERED (Dose administered after 30-day Use By Date), INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Dose 1 administered on 19-Apr-2022 and Dose 2 administered on 02-Jun-2022) and PRODUCT STORAGE ERROR (Vial initially stored in the refrigerator on 21-Apr-2022 and then administered on 02-Jun-2022).    Reported that vial did not undergo any temperature excursions. Reported that patient was administered the Moderna Covid-19 vaccine as second primary series dose by intramuscular injection after the 30 days beyond use date. Patient did not experience any symptoms following vaccination. No additional doses, medications, or treatments have been administered at that time.   This case was linked to US-MODERNATX, INC.-MOD-2022-637076 (E2B Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2022-637076:Patient( C-B)
Patient complained of itching, the area was red on the entire upper arm, and it was warm to the touch.
Back of R arm (at injection site) swelled up, turned red, felt warm to touch, and area felt hard. Patient also states felt feverish and had chills. Went to PCP on 9/10/13 after being referred by pharmacy.
started to get temperature; bone pain; strong headache; dizziness; very tired; has been having elevated blood pressure; This spontaneous case was reported by a physician (subsequently medically confirmed) and describes the occurrence of BONE PAIN (bone pain), HEADACHE (strong headache), DIZZINESS (dizziness), FATIGUE (very tired) and HYPERTENSION (has been having elevated blood pressure) in a 70-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 004M20A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     Concurrent medical conditions included Hypertension and Diabetic. Concomitant products included LOSARTAN, HYDROCHLOROTHIAZIDE, ACETYLSALICYLIC ACID (ASPIRIN (E.C.)), OMEPRAZOLE, METFORMIN and ATORVASTATIN for an unknown indication.    On 18-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 18-Feb-2021, the patient experienced BONE PAIN (bone pain), HEADACHE (strong headache), DIZZINESS (dizziness), FATIGUE (very tired) and HYPERTENSION (has been having elevated blood pressure). On an unknown date, the patient experienced PYREXIA (started to get temperature). At the time of the report, BONE PAIN (bone pain), HEADACHE (strong headache), DIZZINESS (dizziness), FATIGUE (very tired) and HYPERTENSION (has been having elevated blood pressure) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Blood pressure measurement: high (High) high. On an unknown date, Body temperature: unknown (Inconclusive) Unknown.     For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.
Continuously stored in stable FREEZER environment. Only stored in fridge on date of administration for thaw period; 5 Expired Doses Administered - date of administration on 26-Jan-2022; This spontaneous case was reported by an other health care professional and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (5 Expired Doses Administered - date of administration on 26-Jan-2022) and PRODUCT STORAGE ERROR (Continuously stored in stable FREEZER environment. Only stored in fridge on date of administration for thaw period) in a  patient of an unknown age and gender who received mRNA-1273 (Spikevax) (batch no. 020F21A) for COVID-19 vaccination.     No Medical History information was reported.    On 26-Jan-2022, the patient received dose of mRNA-1273 (Spikevax) (unknown route) 1 dosage form. On 26-Jan-2022, the patient experienced EXPIRED PRODUCT ADMINISTERED (5 Expired Doses Administered - date of administration on 26-Jan-2022). On an unknown date, the patient experienced PRODUCT STORAGE ERROR (Continuously stored in stable FREEZER environment. Only stored in fridge on date of administration for thaw period). At the time of the report, EXPIRED PRODUCT ADMINISTERED (5 Expired Doses Administered - date of administration on 26-Jan-2022) and PRODUCT STORAGE ERROR (Continuously stored in stable FREEZER environment. Only stored in fridge on date of administration for thaw period) outcome was unknown.        For mRNA-1273 (Spikevax) (Unknown), the reporter did not provide any causality assessments.   No concomitant medications was reported. No treatment medications was reported.
She had pain and swelling in arm for 1 week. Fever on the first night. She was nauseated and drowsy.
Male 38. With no other disease. With no epilepsy in history.  Convulsions most probably secondary TO COVID VACCINATION
Patient started complaining of extreme back pain and trouble walking within days after receiving the vaccine. His pain got increasingly worse. On the 23rd he had to be taken into the hospital in an ambulance. He said he felt as if his lower body was separated from his torso, and visible was having trouble walking. They prescribed him Valium, preformed an x-ray, and sent him home.  On the 27th he was taken back to the hospital due to leg weakness, tingling in his hands and feet, and extreme pain. He was diagnosed with Guillain-Barre Syndrome. He passed away April 6, 2021 after spending 11 days in the hospital, and 6 days on a ventilator.
Within two hours after the PPSV 23, injection, on arriving home and changing back into normal clothes, I noticed she had a strange mark on her right side chest. At first, I thought it may have been from her bra strap but then I checked the two do not match up. It looked like a cigarette burn mark. Over the next couple of days, this turned into a blister. The blister broke, then scabbed over and took a long time to heal up, as all of these eruptions have.  In the next day or so she started to break out with an extremely itchy rash on her arms and legs. I was applying hydrocortisone cream but that was not enough to control the severe itching, and since her stroke, she has a hard time with control issues. Continued. Within two hours after the PPSV 23, injection, on arriving home and changing back into normal clothes, I noticed she had a strange mark on her right side chest. At first, I thought it may have been from her bra strap but then I checked the two do not match up. It looked like a cigarette burn mark. Over the next couple of days, this turned into a blister. The blister broke, then scabbed over and took a long time to heal up, as all of these eruptions have.In the next day or so she started to break out with an extremely itchy rash on her arms and legs. I was applying hydrocortisone cream but that was not enough to control the severe itching, and since her stroke, she has a hard time with control issues. I contacted her Dr and informed her of the rash going on, and that this was a reaction to the pneumonia vaccine she had the other day and would probably be needing prednisone to help with this rash break out and the severe itching, (yes, I asked for the prednisone).  I was giving my wife the prednisone by her peg tube for a month until the itching finally subsided, and was able to be controlled with the hydrocortisone cream. The rash calmed down but has not stopped, as now she is getting blisters. During this, I did keep in touch with her doctor and also took my wife in to have this looked at by the doctor in December. The numerous rash areas with pop-up small blisters at the time, that, of course, would be scratched open because of the itching, then scab over and take a long time to heal up and fall off. Now February 11, the marks are still very obvious from where most of the rash areas were.Now she is occasionally popping out with larger blisters from the vaccine because there is no other reason for her to develop these blisters on her body.  She has had a couple of these blisters on her lower legs, and now has a large one with two associated smaller blisters on her hip. So this is still an ongoing thing for my poor wife after 3 1/2 months, almost 4 months.  I do have photos of these recent blisters if anyone should be interested.  *** My Wifes Dr. may of also filed on this reaction. Thank you, Husband
pt exp fatigue initially w/SOB which progressively worsened;saw personal MD on 30MAR99 & hosp until 9APR99;dx w/acute hemolytic anemia & cold agglutinin;pt required 9 units of blood;seen & treated by 4 hematologists
Bloody nose twice; This is a spontaneous report from a contactable consumer, the patient. A 15-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 23Jul2021 at 13:15 (at the age of 15-years-old) as a single dose for COVID-19 immunisation. Medical history included bicuspid aortic valve. The patient was allergic to penicillin. The patient did not receive any other medications within 2 weeks of vaccination. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 24Jul2021 at 00:00, the patient experienced bloody nose once and again on the same day at 03:00. The event did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. No therapeutic measures were taken as a result of the event. The clinical outcome of the event bloody nose twice was resolving at the time of this report.   The lot number for BNT162b2 was not provided and will be requested during follow up.
Numbness in the arm/ hand; Cannot lift the arm after a certain point because it hurts; Arm hurts in the area of the shot; Chills; This spontaneous case was reported by a consumer (subsequently medically confirmed) and describes the occurrence of HYPOAESTHESIA (Numbness in the arm/ hand), PAIN IN EXTREMITY (Cannot lift the arm after a certain point because it hurts), VACCINATION SITE PAIN (Arm hurts in the area of the shot) and CHILLS (Chills) in a 76-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 013L20A) for COVID-19 vaccination.     Concurrent medical conditions included Hypertension.    On 21-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 24-Jan-2021, the patient experienced HYPOAESTHESIA (Numbness in the arm/ hand), PAIN IN EXTREMITY (Cannot lift the arm after a certain point because it hurts), VACCINATION SITE PAIN (Arm hurts in the area of the shot) and CHILLS (Chills). The patient was treated with PREDNISONE at a dose of unknown. At the time of the report, HYPOAESTHESIA (Numbness in the arm/ hand), PAIN IN EXTREMITY (Cannot lift the arm after a certain point because it hurts), VACCINATION SITE PAIN (Arm hurts in the area of the shot) and CHILLS (Chills) had not resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       patient uses unspecified medication for high blood pressure as concomitants.
Rash developed 9 days after vaccine and is on shins, knees and both arms. Clear blister like bumps, itchy burning. Ongoing and treating with hydrocortisone.
SINCE THE VACCINE  CHILLS, FEVER SWEATING, HEADACHE, TIREDNESS, DIHARREA, DIZZINESS , TINGLING SENSATION BY FORHEAD ,  TEMPLES  AND FACE ,  CEREBELUM UNTIL TODAY, PLUS  EARLY PERIOD AND LOTS OF BLOOD DURING PERIOD PLUS PAINFULL AND LOTS OF CRAMPS THAT NEVER HAVE BEFORE . PLUS A PRESUSURE ON MY FRONT HEAD AND SOMETIMES FAST PALPITATIONS ON MY HEARTH, AND ON MY LEFT ARM WAS VERY PEAINFULL FOR 3 DAYS AND AT TIMES I SEE LIKE LITLE STARTS IF I MOVE MY HEAD AROUND, ANXIATY .
Headache, fatigue, and extreme vomiting. (10 times during course of night).  Residual headache, fatigue, and lack of appetite for two days after.
I am very nauseous; Very sore throat; Very sort of a terrible headache; Could not eat; not been able to eat anything; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  An 81-year-old female patient received bnt162b2 omi xbb.1.5 (COMIRNATY (2023-2024 FORMULA)), as dose 1, single (Batch/Lot number: unknown), in right arm for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: NAUSEA (non-serious), outcome "unknown", described as "I am very nauseous"; OROPHARYNGEAL PAIN (non-serious), outcome "unknown", described as "Very sore throat"; HEADACHE (non-serious), outcome "unknown", described as "Very sort of a terrible headache"; DECREASED APPETITE (non-serious), outcome "unknown", described as "Could not eat; not been able to eat anything". Therapeutic measures were not taken as a result of nausea, oropharyngeal pain, headache, decreased appetite. Additional ifnormation: The patient reported she was very nauseous, she had been very sore throat. She had been very sort of a terrible headache and she got up to get dressed to go teach this morning and she just lost, she could not do it, she just could not get her clothes on. She could not eat, she had not been able to eat anything and she didn't know what to do for it, she should try to eat or just drink water or any of that. The information on the batch/lot number for bnt162b2 omi xbb.1.5 has been requested and will be submitted if and when received.
Patient came into the pharmacy on Friday, May 20th to receive his second Pfizer COVID booster.  Previous doses (all Pfizer vaccine) were given on 1/29/21, 2/25/21, 10/6/21. Patient completed the standard consent form and the pharmacist spoke with the patient prior to vaccination to answer all questions.  Patient received his booster and waited 15 minutes after vaccination in the pharmacy.  Later in the afternoon, the patient contacted the pharmacy stating he had a half-dollar size purple spot come up on his face, near his eye.  The area was swollen and affecting his vision. The patient stated his vision was blurred.  The patient denied falling, bumping or other trauma to his head or face.  The pharmacist contacted the patient's PCP.  The PCP and pharmacist were in mutual agreement that given the timing and lack of other potential causes, the patient should report to the nearest ER to be further evaluated.  The pharmacist instructed the patient to seek medical care at the nearest emergency room.
Approximately one week after first vaccine, I experienced difficulty standing and loss of strength in my legs. (Both legs felt heavy) I also had increased pain in my lower back.
Severe muscle pain; This case was reported by a consumer via interactive digital media and described the occurrence of muscle pain in a patient who received Herpes zoster (Shingrix) for prophylaxis.   On an unknown date, the patient received Shingrix. On an unknown date, unknown after receiving Shingrix, the patient experienced muscle pain. On an unknown date, the outcome of the muscle pain was unknown.   It was unknown if the reporter considered the muscle pain to be related to Shingrix.     Additional Information: GSK Receipt Date: 02-OCT-2022 Reporter's comment: This case was reported by the patient's via interactive digital media. The reporter stated that he/she had experienced severe muscle pain. Additional supportive information: Follow-up would not possible, as no contact, details were available.